poisar

Stocks · News reference

Vivos Therapeutics Announces 212% Rise YoY Over Most Recent Six-Week Period In Its New Obstructive Sleep Apnea Patient Referrals At Its Nevada Sleep & Airway Medicine Centers

Benzinga Newsdesk

Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

VVOS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K/A filing — Vivos Therapeutics, Inc. (VVOS)

    Filed: 2026-09-08 AccNo: 0001493152-26-041807 Size: 241 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

    VVOS
  3. SEC EDGAR

    8-K filing — Vivos Therapeutics, Inc. (VVOS)

    Filed: 2026-09-08 AccNo: 0001493152-26-041616 Size: 316 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

    VVOS